Objective: To systematically evaluate the literature to determine whether vancomycin-induced neutropenia is dose- or duration-related and provide clinicians with feasible treatment alternatives.

Late-onset neutropenia (LON) is emerging as a common adverse effect to rituximab therapy owing to widespread use of this drug in the treatment of B-cell lymphomas and autoimmune diseases.

Neonatal alloimmune neutropenia is due to maternal production of antibodies directed against neutrophil specific antigens (NA1, NA2, NB1, NC1) reacting with fetal-neonatal and paternal neutrophils.

Mathematical modelling, data science and biostatistics specialist Physiomics announced on Wednesday that its Innovate ...